Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study

BACKGROUND: Sodium-glucose co-transporter-2 inhibitors displayed cardiovascular benefits in type 2 diabetes mellitus in previous studies; however, there were some heterogeneities regarding respective cardiovascular outcomes within the class. Furthermore, their efficacies in Asians, females, and thos...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Jaehyun, Choi, You-Jung, Kim, Bong Sung, Rhee, Tae-Min, Lee, Hyun-Jung, Han, Kyung-Do, Park, Jun-Bean, Na, Jin Oh, Kim, Yong-Jin, Lee, Heesun, Kim, Hyung-Kwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373410/
https://www.ncbi.nlm.nih.gov/pubmed/37496050
http://dx.doi.org/10.1186/s12933-023-01911-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373410/
https://www.ncbi.nlm.nih.gov/pubmed/37496050
http://dx.doi.org/10.1186/s12933-023-01911-7

Ejemplares similares